RIVRESSO Trademark

Trademark Overview

On Wednesday, August 2, 2023, a trademark application was filed for RIVRESSO with the United States Patent and Trademark Office. The USPTO has given the RIVRESSO trademark a serial number of 98113232. The federal status of this trademark filing is NOTICE OF ALLOWANCE - ISSUED as of Tuesday, July 2, 2024. This trademark is owned by Pfizer Inc.. The RIVRESSO trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the treatment of autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular and viral diseases and disorders; pharmaceutical preparations for the treatment of blood disorders, bone growth disorders, skin disorders, arthritis, cancer, hypertension, pain, stroke, obesity and diabetes; pharmaceutical preparations for the treatment of vaso-occlusive crisis and pharmaceutical preparations for the treatment of sickle cell disease; pharmaceutical preparations, namely, anti-infective preparations, medicated dermatological preparations and smoking cessation preparations; vaccines for human use
rivresso

General Information

Serial Number98113232
Word MarkRIVRESSO
Filing DateWednesday, August 2, 2023
Status688 - NOTICE OF ALLOWANCE - ISSUED
Status DateTuesday, July 2, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, May 7, 2024

Trademark Statements

Goods and ServicesPharmaceutical preparations for the treatment of autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular and viral diseases and disorders; pharmaceutical preparations for the treatment of blood disorders, bone growth disorders, skin disorders, arthritis, cancer, hypertension, pain, stroke, obesity and diabetes; pharmaceutical preparations for the treatment of vaso-occlusive crisis and pharmaceutical preparations for the treatment of sickle cell disease; pharmaceutical preparations, namely, anti-infective preparations, medicated dermatological preparations and smoking cessation preparations; vaccines for human use

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateMonday, August 7, 2023
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NamePfizer Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressNew York, NY 10001
Party NamePfizer Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressNew York, NY 10001

Trademark Events

Event DateEvent Description
Saturday, August 5, 2023NEW APPLICATION ENTERED
Wednesday, April 3, 2024ASSIGNED TO EXAMINER
Wednesday, April 3, 2024APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, April 17, 2024NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, May 7, 2024PUBLISHED FOR OPPOSITION
Tuesday, May 7, 2024OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, July 2, 2024NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Monday, August 7, 2023NEW APPLICATION OFFICE SUPPLIED DATA ENTERED

Related Keywords

rivresso preparations pharmaceutical disorders treatment obesity diabetes vaso stroke occlusive pain